Abstract #2259
Differentiating Tumor Progression from Pseudo-progression in Patients with Glioblastomas using DTI and DSC-MRI
Sumei Wang 1 , Maria Martinez-Lage 2 , Yu Sakai 1 , Sanjeev Chawla 3 , Sungheon G Kim 3 , Michelle Alonso-Basanta 4 , Robert A Lustig 4 , Steven Brem 5 , Suyash Mohan 1 , Ronald L Wolf 1 , Arati Desai 6 , and Harish Poptani 1
1
Radiology, University of Pennsylvania,
Philadelphia, PA, United States,
2
Pathology
and Laboratory Medicine, University of Pennsylvania,
Philadelphia, PA, United States,
3
Radiology,
New York University School of Medicine, New York, NY,
United States,
4
Radiation
Oncology, University of Pennsylvania, Philadelphia, PA,
United States,
5
Neurosurgery,
University of Pennsylvania, Philadelphia, PA, United
States,
6
Hematology-Oncology,
University of Pennsylvania, Philadelphia, PA, United
States
The purpose of this study was to determine whether DTI
and DSC MRI can help in differentiating true progression
(TP) from pseudo-progression (PsP) and mixed response in
glioblastoma patients demonstrating enhancing lesions
within six months post chemo-radiation therapy. Nine PsP,
12 mixed response and 21 TP patients underwent DTI and
DSC-MRI. Significantly elevated maximum rCBV (rCBVmax),
FA, CL, CP and decreased CS were observed in TP compared
to PsP. The best logistic regression model to
distinguish TP from non-TP (PsP+mixed) consisted of FA,
CL and rCBVmax (AUC 0.905). DTI and DSC may be helpful
in differentiating PsP from TP.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
